Bioimplants

OrthAdapt Bioimplant granted 501K clearance from U.S. FDA

Published in Medical Letter on the CDC and FDA, September 18th, 2005

Pegasus Biologics, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted 510K clearance for the OrthAdapt Bioimplant, an intelligent, adaptable biologic scaffold that fortifies and promotes tissue remodeling while retaining long-term strength.

This grants Pegasus Biologics clearance to market its bioimplants to reinforce compromised soft tissues in sports medicine, orthopedic, and spine applications.

Pegasus Biologics, Inc. develops novel bioimplants using proprietary technologies.

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-09-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry